Press Release
<< Back
Verastem Initiates Phase 1 Clinical Trial of VS-4718 in Patients with Advanced Cancer
--VS-4718 is the Second Cancer Stem Cell Inhibitor to
Research by the company and
“It is exciting to bring a novel small molecule inhibitor targeting the
FAK pathway, a key regulator of cancer stem cells, into the clinic,”
said Principal Investigator
“We believe that cancer stem cells are ultimately responsible for
disease progression in many cancers,” said Dr.
The Phase 1 trial is an open-label, multicenter, dose-escalation study of VS-4718 in patients. These patients are assessed for safety, pharmacokinetics, pharmacodynamics, and initial evidence of activity as determined by cancer stem cell biomarkers. The study will enroll up to 40 patients at three U.S. locations.
“VS-4718 is the second compound in our portfolio to enter clinical
development,” said
“Our unique understanding of cancer stem cell biology, and diligent
execution by our research and development team, has allowed us to build
a leading portfolio of cancer stem cell targeting agents,” said
For more information on the trial, please visit: http://www.clinicaltrials.gov/ct2/show/NCT01849744.
Upcoming events:
Verastem Annual Research and Development Day
Date:
Time:
Place:
RSVP:
bsullivan@verastem.com
Conference Call Passcode: 60920106
Webcast:
http://phx.corporate-ir.net/phoenix.zhtml?c=250749&p=irol-EventDetails&EventId=4979610
About
Forward-looking statements:
This press release includes forward-looking statements about the
Company’s strategy, future plans and prospects, including statements
regarding the development of the Company’s compounds, including VS-6063,
VS-4718 and VS-5584, and the Company’s FAK, PI3K/mTOR and diagnostic
programs generally, the timeline for clinical development and regulatory
approval of the Company’s compounds and the structure of the Company’s
planned clinical trials. The words “anticipate,” “appear,” “believe,”
“estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,”
“target,” “potential,” “will,” “would,” “could,” “should,” “continue,”
and similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain these
identifying words. Each forward-looking statement is subject to risks
and uncertainties that could cause actual results to differ materially
from those expressed or implied in such statement. Applicable risks and
uncertainties include the risks that the preclinical testing of the
Company’s compounds may not be predictive of the success of later
clinical trials, that the Company will be unable to successfully
complete the clinical development of its compounds, including VS-6063,
VS-4718 and VS-5584, that the development of the Company’s compounds
will take longer or cost more than planned, and that the Company’s
compounds will not receive regulatory approval or become commercially
successful products. Other risks and uncertainties include those
identified under the heading “Risk Factors” in the Company’s Annual
Report on Form 10-K for the year ended
Source:
Verastem, Inc.
Brian Sullivan, 617-252-9314
bsullivan@verastem.com